Current State of Impaired Awareness of Hypoglycaemia in People With Type 1 Diabetes

Diabetes type1 Clinical Trial

Official title:

Current State of Impaired Awareness of Hypoglycaemia in People With Type 1 Diabetes; Change in Prevalence, Impact of Glucose Monitoring Technology and Psychosocial Impact

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04311021
• Other study ID #: NL-number: NL71207.091.19
• Status: Recruiting
• Start date: January 23, 2020
• Est. completion date: February 1, 2021

Study information

• Verified date: February 2020
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rationale:

Hypoglycaemia is the most frequent complication of insulin treatment in individuals with type 1 diabetes and a limiting factor for achieving optimal glycaemic control. When recurrent, hypoglycaemia can induce a process of habituation, leading to impaired awareness of hypoglycaemia (IAH), a process that can be reversed by meticulous avoidance of hypoglycaemia. In the past 5-10 years, the use of continuous real-time (RT-CGM) or flash glucose monitoring (FGM) has increased rapidly in the clinical management of type 1 diabetes to improve overall glycaemic control and reduce the frequency of hypoglycaemic events, in particular in patients with IAH. It is unknown, however, whether the use of these devices, as well as other improvements in clinical management, has reduced the prevalence IAH and exposure to severe hypoglycaemia (SH) in subjects with type 1 diabetes in a real-world setting. Therefore, it becomes highly appropriate to investigate the current state of IAH and SH in type 1 diabetes. Also, since invites to this study will specifically include people who have taken part of previous assessments, this study will be able to investigate the change in IAH over time and the potential contributing role of RT-CGM/FGM. Furthermore, we want to explore associations of IAH and SH with clinical parameters, quality of life and psychosocial impact. This knowledge will help people with diabetes and their healthcare providers to better adjust treatment recommendations to individual targets.

Objective:

The primary objective of our study is to investigate the current prevalence of IAH and exposure to severe hypoglycaemia in individuals with diabetes type 1.

The secondary objectives of our study are to:

• Study the difference in IAH prevalence over time in individuals with diabetes type 1.

• Assess the association of RT-CGM/FGM with IAH and SH.

• Study thoughts, emotions and worries which lead to a certain behaviour in case of hypoglycaemia and prevention of hypoglycaemia.

• Study associations of IAH and history of SH with productivity in different situations (work/study, relation/sexuality, driving behaviour/traffic and sport/leisure).

• Study association between partner involvement and handling in case of (unawareness for) hypoglycaemia.

• Study knowledge of subjects with diabetes about hypoglycaemia and IAH.

• Study burden of IAH and severe hypoglycaemia on family members of people with type 1 diabetes, as experienced by patients themselves.

Study design:

This study will be a cross-sectional observational cohort study. The study will be conducted at the Radboud university medical center, department of internal medicine. Subjects with type 1 diabetes will be recruited from outpatient diabetes clinic as well as subjects who participated in two earlier cohorts and agreed to be approached again.

Study population:

The study population will be individuals with diabetes type 1, older than sixteen years old.

Main study parameters/endpoints The main study parameter will be the current prevalence of IAH and exposure to severe hypoglycaemia in the past 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 700
• Est. completion date: February 1, 2021
• Est. primary completion date: February 1, 2021
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Type 1 diabetes diagnosis based on clinical judgement with or without auto-antibodies, according to the ISPAD Clinical Practice Consensus Guidelines 2018 (27). Briefly, clinical criteria for the diagnosis of diabetes mellitus include an acute presentation, classical symptoms of diabetes or profound hyperglycaemia with or without ketoacidosis, a plasma glucose concentration =11.1 mmol/L and considerably elevated HbA1c, and age of onset >6 months.

• Age =16 years.

• Ability to provide written informed consent.

• Fluency in speaking and reading Dutch.

Exclusion Criteria:

• Severe psychiatric comorbidity that leads to inability to provide informed consent or as judged by the healthcare provider

• Other comorbidity interfering with completing surveys, as judged by the healthcare professional.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes type1
• Hypoglycemia

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen

Sponsors (2)

Lead Sponsor	Collaborator
Radboud University	HypoResolve

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The main study parameter will be the current prevalence of IAH and exposure to SH in the past 12 months.		Past 12 months
Secondary	Difference in IAH prevalence over the years.		Past 12 years.
Secondary	Relationship between IAH/SH prevalence and RT-CGM/FGM vs traditional glucometer use.		Past 12 months.
Secondary	Answers to questionnaire		Past 12 months.

External Links

•   Related Info